Kiotech International PLC floated on AIM at 7p, June 2005. They are a provider of pheromone technologies in fish farming and commercial fishing. Kiotech focuses on developing products containing synthetic versions of pheromones (natural signaling chemicals) designed to attract and stimulate feeding in fish.

Kiotech Website: http://www.kiotech.com/

Kiotech Presentation: http://kiotech.com/two-col.php?pageName=presentation

In November 2006 KIO reversed into Agil, a division of Lawrence PLC for 5.25M plus 8,333,334 Ordinary Shares at the Placing Price of 3p. Agil generated a profit before interest and tax of 755,000 on sales of 5,235,000 for the 12 months to 31 March 2006.

KIO in partnership with the UK Government Agency CEFAS (the Centre for Environment, Fisheries & Aquaculture Science) and in collaboration with local aquaculture and fish institutes in China and Thailand, has been conducting large-scale trials at commercial aquaculture facilities.

These trials were set up, following successful laboratory results, to assess the efficacy of the Company's pheromone-based feeding attractants in full scale commercial situations.

The trials, which were carried out under the supervision of CEFAS, have now been completed and the results analysed by CEFAS. Initial results from these trials
have been very encouraging and the results are summarised below:-

Six month commercial trial, Tilapia* (Oreochromis niloticus), Zhouhai, China

The species Tilapia gained 17% more weight as compared to control
Accelerated rate of fish growth allowed harvesting of Tilapia 3 weeks early
Fish appeared healthier and better water quality
Secondary crop of White Shrimp (grown in same ponds) significantly higher with less disease
Overall the farmer received a 50% higher income from the pond treated with the Kiotech product, as compared to the control pond.

Tilapia, whilst relatively unknown in Europe, is commercially important in Asia and of increasing importance in USA. In 2005 1 million metric tonnes were farmed in China. (Source USDA: United States Department of Agriculture:)

Three month commercial trial, White Shrimp (Litopenaeus vannamei), Tradt, Thailand

The White Shrimp were 30% larger on average than the control shrimp
Less feed was required probably due to increased feed take up by the shrimp resulting in lower food wastage.
Shrimp had a lower food conversion ratio (FCR) compared to the control

Conclusion

These results demonstrate the potential for very significant commercial benefits to the participating farmers operating in multi billion dollar global aquaculture market, as well as producing equally significant environmental benefits.

This gives us much encouragement to press on with the development of products
tailored to other commercially important species.

The strategy is to now to obtain full regulatory approval for these products and start commercial sales as soon as possible thereafter. We are discussing a joint venture agreement for production and distribution of our products in China, the largest market for the species covered by the trials. We aim to bring a product to the market by the middle of 2008 although it is possible that we may be able to achieve sales before this date.

Richard Rose, Chairman of Kiotech commented:

"These are very exciting results and demonstrate the effectiveness of our
pheromone-based technology. We can now commence work on commercialising these products which I am confident will have a significant effect on the
productivity, efficiency and sustainability of the world wide aquaculture industry"

Signficant Holdings

A large proportion of the shares in issue, 251,078,696, are held by Institutions, resulting in lack of liquidity but importantly significant SP movements on low volume.

Artemis VCT2 4.08%
F & C Asset Management 14.44%
First State Aim VCT 1.43%
J P Morgan Asset Management 1.41%
N C J Scott 0.95%
RBS British Smaller Co. Fund 1.43%
Unicorn Asset Management 13.28%
Williams de Broe 4.86%
ISIS EP LLP 13.28%
Wills & CO Stockbrokers 2.33%
City Equities Limited 3.98%
Invesco Perpetual Aim VCT 9.38%
AXA S.A. 7.49%

Total 78.34%

(Note: The nature of the holdings have been obtained from the 2006 Reverse Take-Over Admission Document and updated where information exists in the form of RNS notifications; however, some of the holdings are below the notifiable interest level and may no longer reflect the current situation).



Obviously early days for KIO, but the recent successful trials and impending commercialisation no later than next year makes this an interesting company with considerable potential in a huge market.

offering at 5.25p at mo, ie mid point of spread, heard that was not a good sign when i topped up with CHP buying at 12.25 (which was midpoint at the time), which proved to be good advice... hmmmm

no problem buying 100k at that price...

That's a fair point Ted; certainly 10 days ago it was impossible to buy more than 10,000, so it it would appear someone has offloaded some stock. But to be honest, this is a long term hold for me, so daily trades hold just a little interest to judge short term sentiment, but no more than that.

pth

yes this is one of those interestingly boring stocks... lol
hopefully a nice growth story... although i don't have any (yet)

Nice 11% rise today, don't know if any of you guys have been buying over the last two days, but the SP is certainly looking perky :)

l now hold quite a few actually... ...What with a mere 22% of issued shares being up for grabs as a consequence of institutional positions , l see some volatility on light volume here which will reward initially trader and then investor alike ..@+ J

Hmm, wonder why 4 small trades dropped the price nearly 13%, either someone offloading and trade yet to be reported or a bit of a shake perhaps, not that I believe in shakes of course :)

Steady progress the order of the day:

Kiotech International plc, the supplier of high performance natural feed
additives to the aquaculture and agriculture markets, is holding its AGM later
today, at which Richard Rose, Chairman, will make the following statement.

`We are pleased with the progress management is making bedding in the Agil
acquisition and also focusing on improving the gross margin and developing new
products and territories. Agil has recently taken its first order in Sri Lanka
for Salkil (poultry feed additive which reduces likelihood of salmonella and
E.coli) and its Bactacid product (Salkil equivalent for pigs) has been well
received in the Ukraine - a new territory which we believe has good potential.

We are in the final stages of agreeing a joint venture in China, with Kiotech as
the majority shareholder; this should help with the process of registering
Aquatice (chemosensory stimulant for fish feeding) in that country. We have
received considerable international interest in Aquatice from the aquaculture
industry and are taking steps to work with some of these parties to progress the
commercial development of the product.'

http://www.bayer.com.vn/bayzine/index.asp?act=XemChiTiet&Cat_ID=37&News_ID=267&LinksFrom=http://www.bayer.com.vn/bayzine/index.kp

Dont know if That Lat is the fish under trials in Vietnam,perhaps its Vietnamese for Tilapia.

"Kiotech has signed an agreement to work with Bayer HealthCare, which is carrying out a series of Aquatice(R) trials in that country under the direction of Cefas which, if successful, will lead to both companies signing a distribution agreement for the Vietnamese aquaculture market. "

The directors of e-Therapeutics plc (AIM: ETX), Advanced Cell Technology (OTCBB: ACTC), Kiotech International (AIM: KIO) and Camco International (AIM: CAO) will be presenting:

Thursday the 14th October 2010, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.

This event is suitable for the following: Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

FREE registration - http://www.proactiveinvestors.co.uk/register/event_details/90

If you have any problems registering or queries please email events@proactiveinvestors.com.